Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | TDO2 | P48775 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.45 |
| ▸ | PDE2A | O00408 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL140922 | 1.00 | ADRB2 (1.00) | ADRB2SLC6A3SLC6A2LMNATP53 | |
| SCHEMBL177057 | 1.00 | ADRB2 (1.00) | ADRB2SLC6A3SLC6A2LMNATP53 | |
| Bromide SCHEMBL28703130 | 0.97 | ADRB2 (0.95) | ADRB2SLC6A3SLC6A2LMNATP53 | |
| Iodide SCHEMBL29127483 | 0.97 | ADRB2 (0.95) | ADRB2SLC6A3SLC6A2LMNATP53 | |
| Hydrochloric Acid SCHEMBL2459100 | 0.97 | ADRB2 (0.95) | ADRB2SLC6A3SLC6A2LMNATP53 | |
| Hydrochloric Acid SCHEMBL25383293 | 0.97 | ADRB2 (0.95) | ADRB2SLC6A3SLC6A2LMNATP53 | |
| Hydrochloric Acid SCHEMBL1924682 | 0.97 | ADRB2 (0.95) | ADRB2SLC6A3SLC6A2LMNATP53 | |
| SCHEMBL10804179 | 0.93 | ADRB2 (0.86) | ADRB2SLC6A3SLC6A2LMNATP53 | |
| SCHEMBL1314596 | 0.85 | ADRB2 (0.72) | ADRB2LMNAHTTTSHRHIF1A | |
| SCHEMBL17540834 | 0.82 | ADRB2 (0.70) | ADRB2LMNAHTTIDO1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 452 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250078176-A1 | ENVIRONMENTAL ATTRIBUTES FOR NITROGEN CONTAINING CHEMICALS | BASF SE (DE) | 2025-03-06 | — | — | US | claimed |
| CN-119552185-A | Method for recycling 4-BMA from 4-BMA mother liquor recycling material by using chiral amine | 济南大学 | 2025-03-04 | — | — | CN | claimed |
| CN-118435582-A | Environmental attributes of nitrogen-containing chemicals | 巴斯夫欧洲公司 | 2024-08-02 | — | — | CN | claimed |
| WO-2023117926-A1 | ENVIRONMENTAL ATTRIBUTES FOR NITROGEN CONTAINING CHEMICALS | BASF SE (DE) | 2023-06-29 | — | — | WO | claimed |
| CN-111944515-B | Circular polarization luminescent material and preparation method and application thereof | 中国科学院化学研究所 | 2022-05-10 | — | — | CN | claimed |
| CN-111944515-A | Circular polarization luminescent material and preparation method and application thereof | 中国科学院化学研究所 | 2020-11-17 | — | — | CN | claimed |
| CN-109851506-B | Asymmetric reductive amination of simple ketones catalyzed by ruthenium-bisphosphine catalysts to prepare chiral primary amines | 凯特立斯（深圳）科技有限公司 | 2020-09-15 | — | — | CN | claimed |
| US-9133187-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-15 | — | — | US | claimed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| EP-2735560-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-METHYLPROLINE DERIVATIVE | Kaneka Corporation (JP) | 2014-05-28 | — | — | EP | claimed |
| US-8084630-B2 | Process for the synthesis of ramelteon and its intermediates | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-12-27 | — | — | US | claimed |
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-11-12 | — | — | US | claimed |
| EP-2098519-A1 | Process for the synthesis of ramelteon and its intermediates | Teva Pharmaceutical Industries Ltd. (IL) | 2009-09-09 | — | — | EP | claimed |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | US | claimed |
| US-5144077-A | PROCESS FOR WORKING UP THE CRYSTALLIZATION MOTHER LIQUOR FROM THE RESOLUTION OF THE RACEMATE OF 1-(4-CHLOROPHENYL)-ETHYLAMINE | BAYER AKTIENGESELLSCHAFT (DE) | 1992-09-01 | — | — | US | claimed |
| EP-4698170-A1 | GLYCINAMIDE DERIVATIVES FOR USE IN THE TREATMENT OF SALMONELLOSIS | Eberhard-Karls-Universität Tübingen (DE) | 2026-02-25 | — | — | EP | disclosed |
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | CEREVANCE INC (US) | 2025-09-11 | — | — | US | disclosed |
| EP-0341475-A2 | Stereo isomers of N-(R)-1-aryl-ethyl)-1-alkyl-2,2-dichlorocyclopropane carboxamide | BAYER AG (DE) | 1989-11-15 | — | — | EP | disclosed |
| CN-1035827-A | The 4-oxo of opticity-1-chromene-2-carboxylic acid derivative and intermediates preparation thereof | SANWA KAGAKU KENKYUSHO K K (JP) | 1989-09-27 | — | — | CN | disclosed |
| EP-0331078-A2 | Process for the preparation of optically active 4-oxo-1-benzopyran-2-carboxylic acid derivatives and intermediates thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1989-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | ADRB2 1490/4885SLC6A3 2744/4885SLC6A2 3015/4885 |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | ADRB2 1661/4885SLC6A3 1207/4885SLC6A2 893/4885 |
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | GPR55, GPR68, GPR65 | ADRB2 45/4885SLC6A3 544/4885SLC6A2 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.